PIS
RVNC

POM Investment Strategies’s Revance Therapeutics, Inc. RVNC Stock Holding History

POM Investment Strategies’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2,583
Closed -$7.85K – 384
2024
Q4 		$7.85K Hold
2,583
– – 0.01% 188
2024
Q3 		$13.4K Hold
2,583
– – 0.01% 121
2024
Q2 		$6.64K Hold
2,583
– – 0.01% 211
2024
Q1 		$12.7K Hold
2,583
– – 0.01% 106
2023
Q4 		$22.7K Buy
+2,583
New +$21.2K 0.02% 85

Other funds holding RVNC

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

POM Investment Strategies's RVNC Position: Q1 2025 in Review

POM Investment Strategies sold out of Revance Therapeutics, Inc. (RVNC) in Q1 2025, closing a stake of 2,583 shares — an estimated $7.85K sold.

POM Investment Strategies first reported a position in RVNC in Q4 2023 and held it in 5 quarters. The position peaked at $22.7K in Q4 2023. 1 fund tracked by Wall St. Rank holds RVNC as of Q1 2025.

  • POM Investment Strategies reported no remaining Revance Therapeutics, Inc. position as of Q1 2025 after selling out during the quarter.
  • POM Investment Strategies sold 2,583 Revance Therapeutics, Inc. shares in Q1 2025, an estimated $7.85K.
  • POM Investment Strategies first reported a position in Revance Therapeutics, Inc. in Q4 2023 and held it in 5 quarters.
  • POM Investment Strategies's Revance Therapeutics, Inc. position peaked at $22.7K in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q1 2025.

Based on POM Investment Strategies's 13F filing for Q1 2025, filed 30 Apr 2025.